Why is PFE stock falling today despite beating Pfizer's earnings estimates? Key factors investors are watching

PFE stock today: Pfizer shares fell on Tuesday even after the pharmaceutical giant reported fourth-quarter results that topped analysts’ estimates, reflecting the market’s mixed reaction to the company’s modest 2026 guidance. The dip highlights investor concerns over declining demand for Covid-related products and slower growth from older drugs.

PFE Stock (Pfizer) Falls Despite Beating Q4 Earnings Expectations

The company is turning its attention to long-term growth opportunities, including its $10 billion acquisition of obesity biotech Metsera, as per a report. Pfizer showcased the potential of that investment by releasing mid-stage data showing that a monthly Metsera obesity injection can help patients achieve significant weight loss, signaling a promising avenue beyond Covid-related revenue, as per a CNBC report.

Cost reduction is also a priority, with Pfizer targeting approximately $7.7 billion in savings by the end of 2027 through two separate initiatives.


Also read: PayPal stock (PYPL) crashes 17% after weak Q4 earnings - Enrique Lores to replace Alex Chriss as CEO

Pfizer Earnings: Adjusted EPS Surpasses Analyst Forecast at 66 Cents

For the fourth quarter, Pfizer posted adjusted earnings per share of 66 cents, exceeding Wall Street’s forecast of 57 cents. Revenue came in at $17.56 billion, above the expected $16.95 billion, though slightly down around 1% from the same period a year ago due to waning demand for its Covid vaccine and antiviral pill Paxlovid.

PFE Stock Down Today After Net Loss of $1.65 Billion Driven by Restructuring and Intangible Costs

Despite the strong adjusted results, the company recorded a net loss of $1.65 billion, or 29 cents per share, compared with net income of $410 million, or 7 cents per share, during the same quarter in 2025. Excluding items such as restructuring charges and intangible asset costs, the adjusted figures showed a stronger underlying performance.

Also read: Word of the day: Ergophobia

Pfizer 2026 Guidance Projects Flat Revenue and Modest Profit

Pfizer expects adjusted profit in 2026 to range between $2.80 and $3 per share, with revenue projected at $59.5 billion to $62.5 billion, largely flat compared with 2025, as per the CNBC report.

Declining Covid Sales and Product Exclusivity Challenges Pfizer Stock

The company attributed part of the modest outlook to declining Covid product sales, which it expects to drop by about $1.5 billion year over year to $5 billion, and another $1.5 billion in revenue loss from products losing market exclusivity.

Medicaid Pricing Agreement Impacts Margins and Profit Outlook

Some of Pfizer’s blockbuster drugs, such as the pneumonia vaccine Prevnar, face increasing competition from rivals. Additionally, CFO Dave Denton noted in December that the 2026 guidance incorporates “price compression and margin compression,” particularly in the Medicaid business, as part of a landmark drug pricing agreement with the Trump administration, as per the CNBC report.

Under the deal, Pfizer will sell existing drugs to Medicaid patients at the lowest price offered in other developed countries and guarantee similar pricing for new drugs across Medicare, Medicaid, and commercial payers. In return, the company will receive a three-year exemption from tariffs.

Pipeline Developments Including Xeljanz and Obesity Treatments Offer PFE Stock Investor Confidence

Beyond Covid products, investors are closely monitoring Pfizer’s pipeline. Treatments like Xeljanz and Xeljanz XR, used for rheumatoid arthritis and inflammatory conditions, were selected in January for the third round of Medicare drug price negotiations, with new negotiated prices expected to take effect in 2028.

FAQs

Why did Pfizer stock drop even after beating earnings?
Investors were concerned about modest 2026 guidance and declining Covid product sales.

What were Pfizer’s Q4 earnings?
Adjusted earnings per share were 66 cents, beating expectations of 57 cents.